Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

“We are encouraged by these initial Phase 2 safety and immunogenicity data on our ACI-7104.056 active immunotherapy being studied in early Parkinson’s disease. The level of immunogenicity after only 3 ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...